SubHero Banner

Darzalex Faspro® (daratumumab and hyaluronidase-fihj) – Expanded indication

July 12, 2021 - Janssen announced the FDA approval of Darzalex Faspro (daratumumab and hyaluronidase-fihj), in combination with Pomalyst® (pomalidomide) and dexamethasone, for the treatment of adult patients with multiple myeloma in patients who have received at least one prior line of therapy including Revlimid® (lenalidomide) and a proteasome inhibitor.

Download PDF